Cite
HARVARD Citation
Lind, M. et al. (n.d.). Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. Lung cancer. pp. S49-S50. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Lind, M. et al. (n.d.). Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. Lung cancer. pp. S49-S50. [Online].